3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Burkitt Lymphoma
5
Prostatic Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Leukemia, Biphenotypic, Acute
2
Hematologic Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostate Cancer Recurrent
1
Philadelphia Chromosome
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia
1
Glioma
1
Interventions
ponatinib
4
Methotrexate
4
Cytarabine
4
Cyclophosphamide
4
merphos
3
Whole-Body Irradiation
3
Peripheral Blood Stem Cell Transplantation
3
Mycophenolic Acid
3
venetoclax
2
fludarabine phosphate
2
Tacrolimus
2
Idarubicin
2
Etoposide
2
Cyclosporine
2
Cladribine
2
Busulfan
2
prednylidene
1
nilotinib
1
midostaurin
1
gilteritinib
1
fludarabine
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
deltacortene
1
bosutinib
1
blinatumomab
1
auricularum
1
asciminib
1
Vincristine
1
Thiotepa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Blast Crisis
×
Dasatinib
×
90 days
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled